A patient death in a phase 1 trial of Mersana Therapeutics’ antibody-drug ... which is developing the STING agonist in collaboration with GSK under the terms of a $1.3 billion option deal ...
Mersana plans to continue enrolling patients in dose escalation and expects to present initial clinical pharmacodynamic STING activation data for XMT-2056 in 2025. Mersana continues to advance its ...
Martin Huber; President, Chief Executive Officer, Director; Mersana Therapeutics Inc Brian ... 2056 is our immunosynthen STING agonist ADC targeting a novel epitope of HER2. Later in 2025, we ...
Mersana plans to continue enrolling patients in dose escalation and expects to present initial clinical pharmacodynamic STING activation data for XMT-2056 in 2025. Mersana continues to advance its ...
Mersana plans to continue enrolling patients in dose escalation and expects to present initial clinical pharmacodynamic STING activation data for XMT-2056 in 2025. Mersana continues to advance its ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback